Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carol S Lim

Showing results (31-40 of 56) with videos related to

Pageof 6
Sort By:
Molecular Pharmaceutics|August 7, 2013
Multidomain targeting of Bcr-Abl by disruption of oligomerization and tyrosine kinase inhibition: toward eradication of CMLGeoffrey D Miller, David W Woessner, Monika J Sirch, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2023
Computational Modeling of Stapled Coiled-Coil Inhibitors Against Bcr-Abl: Toward a Treatment Strategy for CMLMaria Carolina P Lima, Braxten D Hornsby, Carol S Lim, et al.
The Journal of Physical Chemistry. B|July 1, 2024
Molecular Modeling of Single- and Double-Hydrocarbon-Stapled Coiled-Coil Inhibitors against Bcr-Abl: Toward a Treatment Strategy for CMLMaria Carolina P Lima, Braxten D Hornsby, Carol S Lim, et al.
Therapeutic Delivery|December 17, 2019
Advances in delivery vectors for gene therapy in liver cancerKatherine E Redd Bowman, Phong Lu, Erica R Vander Mause, et al.
Molecular Pharmaceutics|March 3, 2012
Direct induction of apoptosis using an optimal mitochondrially targeted p53Mohanad Mossalam, Karina J Matissek, Abood Okal, et al.
The Journal of Physical Chemistry. B|July 3, 2025
Correction to "Molecular Modeling of Single- and Double-Hydrocarbon-Stapled Coiled-Coil Inhibitors against Bcr-Abl: Toward a Treatment Strategy for CML"Maria Carolina P Lima, Braxten D Hornsby, Carol S Lim, et al.
Pharmaceutical Research|December 21, 2011
Changing the subcellular location of the oncoprotein Bcr-Abl using rationally designed capture motifsAndrew S Dixon, Jonathan E Constance, Tomoyuki Tanaka, et al.
Molecular Pharmaceutics|September 11, 2012
Enhanced and selective killing of chronic myelogenous leukemia cells with an engineered BCR-ABL binding protein and imatinibJonathan E Constance, David W Woessner, Karina J Matissek, et al.
Molecular Pharmaceutics|August 23, 2013
A chimeric p53 evades mutant p53 transdominant inhibition in cancer cellsAbood Okal, Mohanad Mossalam, Karina J Matissek, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 6, 2026
Therapeutic peptides and proteins: Status and developments in drug deliveryBraxten D Hornsby, Cheng Hua Lee, Cassidy A Steele, et al.
Pageof 6

Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
Molecular Pharmaceutics|August 7, 2013
Multidomain targeting of Bcr-Abl by disruption of oligomerization and tyrosine kinase inhibition: toward eradication of CMLGeoffrey D Miller, David W Woessner, Monika J Sirch, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2023
Computational Modeling of Stapled Coiled-Coil Inhibitors Against Bcr-Abl: Toward a Treatment Strategy for CMLMaria Carolina P Lima, Braxten D Hornsby, Carol S Lim, et al.
The Journal of Physical Chemistry. B|July 1, 2024
Molecular Modeling of Single- and Double-Hydrocarbon-Stapled Coiled-Coil Inhibitors against Bcr-Abl: Toward a Treatment Strategy for CMLMaria Carolina P Lima, Braxten D Hornsby, Carol S Lim, et al.
Therapeutic Delivery|December 17, 2019
Advances in delivery vectors for gene therapy in liver cancerKatherine E Redd Bowman, Phong Lu, Erica R Vander Mause, et al.
Molecular Pharmaceutics|March 3, 2012
Direct induction of apoptosis using an optimal mitochondrially targeted p53Mohanad Mossalam, Karina J Matissek, Abood Okal, et al.
The Journal of Physical Chemistry. B|July 3, 2025
Correction to "Molecular Modeling of Single- and Double-Hydrocarbon-Stapled Coiled-Coil Inhibitors against Bcr-Abl: Toward a Treatment Strategy for CML"Maria Carolina P Lima, Braxten D Hornsby, Carol S Lim, et al.
Pharmaceutical Research|December 21, 2011
Changing the subcellular location of the oncoprotein Bcr-Abl using rationally designed capture motifsAndrew S Dixon, Jonathan E Constance, Tomoyuki Tanaka, et al.
Molecular Pharmaceutics|September 11, 2012
Enhanced and selective killing of chronic myelogenous leukemia cells with an engineered BCR-ABL binding protein and imatinibJonathan E Constance, David W Woessner, Karina J Matissek, et al.
Molecular Pharmaceutics|August 23, 2013
A chimeric p53 evades mutant p53 transdominant inhibition in cancer cellsAbood Okal, Mohanad Mossalam, Karina J Matissek, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 6, 2026
Therapeutic peptides and proteins: Status and developments in drug deliveryBraxten D Hornsby, Cheng Hua Lee, Cassidy A Steele, et al.
Pageof 6